PRESS RELEASES

Philips and Merck partner to advance personalized fertility treatment

January 14, 2021

Remote patient monitoring, cloud-based platform services and mobile, AI-enabled ultrasound diagnostics to support improved access to care and better outcomes in fertility treatment

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a multi-year partnership with Merck, a leading science and technology company, to develop clinical-grade digital solutions for highly personalized fertility treatment. Leveraging digital health technologies, advanced informatics and mobile, AI-enabled ultrasound diagnostics, these solutions will aim to better inform patients and clinicians about the choice and timing of fertility treatment to maximize the chances of conception.

“At Philips we are leading digital transformation in healthcare, with a portfolio that includes solutions for both professionals and consumers to support parents-to-be through pregnancy and the first years of their baby’s life,” said Jeroen Tas, Chief Innovation & Strategy Officer, Royal Philips. “The journey for aspiring parents is sometimes a difficult one, and by collaborating with Merck, a world leader in fertility treatment, we aim to develop integrated digital solutions that improve the patient experience and can ultimately have a positive impact on health outcomes. This partnership builds on our expertise in maternal and fetal monitoring, our Pregnancy+ and Baby+ consumer engagement apps, our leading ultrasound solutions and our HealthSuite Cloud/AI platform.”

“We believe that the future of IVF will be unlocked through digital health technologies that empower professionals and patients to be better connected,” said Michelangelo Canzoneri, Global Head of Digital and Data, Healthcare at Merck. “With Philips, we have a partner that shares our belief in the potential of digital health to improve the patient experience, bringing a wealth of experience in connected care to our offering. Together, this collaboration will push our two companies to think beyond tomorrow and discover new solutions that can empower people to realize their dreams of parenthood,” added Jan Kirsten, Head of Global Business Franchise for Fertility at Merck.

Digital health and virtual care technologies have proved invaluable during the COVID-19 pandemic in keeping patients and their care teams in virtual contact, accelerating digital transformation in healthcare. Digital technologies including remote patient monitoring, cloud-based services and AI are playing an ever more important part in achieving better patient outcomes, better patient and staff experiences, and low cost of care – the quadruple aim of healthcare.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel.: +31 631 639 916
E-mail: [email protected]
Twitter: mark_groves

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Merck

Merck KGaA, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of €16.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

Attachment

Latest News

‫ศาลอุทธรณ์มอบชัยชนะครั้งสำคัญให้กับ TriMax เหนือ Wickfire

ศาลอุทธรณ์ภาคห้าออกคำตัดสินชี้ขาดว่า TriMax Media ไม่ได้กระทำการละเมิดกฎหมายใดๆ ต่อ Wickfire L.L.C. ในขณะที่เห็นพ้องต่อคำตัดสินของคณะลูกขุนที่ว่า Wickfire แทรกแซงธุรกิจของ TriMax โดยเจตนา ดัลลัส, March 08, 2021 (GLOBE NEWSWIRE) — หลังจากที่มีการฟ้องร้องมาเจ็ดปี TriMax ได้รับชัยชนะเหนือ Wickfire เมื่อวันที่ 26 กุมภาพันธ์ 2021 ศาลอุทธรณ์ได้ออกคำตัดสินขั้นสุดท้ายว่า Wickfire ไม่มีหลักฐานใดๆ ที่จะสนับสนุนข้อเรียกร้องต่อ TriMaxคำตัดสินดังกล่าวเกิดขึ้นในศาลอุทธรณ์ภาคห้าของสหรัฐอเมริกา หมายเลขคดี 17-3043040คำตัดสินของศาลอุทธรณ์ได้กลับคำตัดสินค่าความเสียหายที่เป็นตัวเงินทั้งหมดที่มอบให้กับ Wickfire ก่อนหน้านี้ คดีความนี้แต่เดิมพิจารณาโดยเขตตะวันตกของรัฐเท็กซัส หมายเลขคดี14-CV-34 ในประเด็นเกี่ยวกับ Google AdWords Auction ซึ่งเป็นแพลตฟอร์มการประมูลออนไลน์ที่บริษัทต่างๆ เช่น TriMax และ Wickfire ได้แข่งขันกันเพื่อพื้นที่โฆษณาWickfire ยืนกรานเรียกร้องต่อ TriMax หลายข้อ แต่ท้ายที่สุด Wickfire ก็ล้มเหลวในทุกข้อ: Wickfire […]

Synchronoss Announces Appointment of Jeff Miller as Permanent CEO and President

BRIDGEWATER, N.J., March 08, 2021 (GLOBE NEWSWIRE) —  Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator of cloud, messaging and digital solutions, today announced that its Board of Directors has confirmed Jeff Miller as its President and Chief Executive Officer. Miller had been serving as interim President and CEO of Synchronoss since September 2020 and joined […]

iRemedy Procures Supply of 500 Million More Low-Dead Space Syringes and Needles in Support of “Project Vaccinate”

STUART, Fla., March 08, 2021 (GLOBE NEWSWIRE) — The iRemedy Healthcare Companies, Inc. (“iRemedy” or “the Company”), pioneer of the iRemedy™ medical supply marketplace, today announced that the Company has arranged for the procurement of an additional 500 million low-dead space syringes and needles in association with iRemedy’s “Project Vaccinate” initiative, created to support global […]

Famed Attorney CHARLES HARDER Releases Book GAWKER SLAYER on Fifth Anniversary of $140 Million Trial Victory For Hulk Hogan Against Gawker Media

GAWKER SLAYER Dubbed “the highest-profile media lawyer in America” by The Hollywood Reporter, and “Hollywood’s favorite lawyer,” by Financial Times, CHARLES HARDER gives readers an inside look at his most famous celebrity cases during his 25-year career. NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) — Coinciding with the fifth anniversary of the landmark $140 million jury […]